January 26, 2015 12:08 PM ET

Biotechnology

Company Overview of EPIRUS Biopharmaceuticals, Inc.

Company Overview

EPIRUS Biopharmaceuticals, Inc., a commercial-stage biotechnology company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. Its pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) for the treatment of inflammatory diseases; BOW030, a biosimilar version of Avastin (bevacizumab) to treat various cancers; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. The co...

699 Boylston Street

8th Floor

Boston, MA 02116

United States

Founded in 2011

Phone:

617-600-3497

Key Executives for EPIRUS Biopharmaceuticals, Inc.

Chief Executive Officer
Total Annual Compensation: $375.0K
Chief Financial Officer
Total Annual Compensation: $160.4K
Senior Vice President of Clinical
Total Annual Compensation: $280.0K
Compensation as of Fiscal Year 2013.

EPIRUS Biopharmaceuticals, Inc. Key Developments

EPIRUS Biopharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

EPIRUS Biopharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

EPIRUS Biopharmaceuticals, Inc. Launches its First Product Infimab in India

EPIRUS Biopharmaceuticals, Inc. announced the launch of its first product, Infimab (BOW015), the first infliximab biosimilar in India. Infimab, a Remicade (infliximab) biosimilar, is being launched in cooperation with EPIRUS' commercialization partner Ranbaxy Laboratories Limited (Ranbaxy). Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai.

Epirus Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

EPIRUS Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $13,929,000 against $3,026,000 a year ago. Loss before income taxes was $13,935,000 against $4,294,000 a year ago. Net loss was $13,935,000 against $4,278,000 a year ago. Basic and diluted loss per share was $1.28 against $18.05 a year ago. For the nine months, the company reported loss from operations of $29,100,000 against $10,637,000 a year ago. Loss before income taxes was $31,427,000 against $13,038,000 a year ago. Net loss was $31,445,000 against $13,022,000 a year ago. Basic and diluted loss per share was $8.15 against $55.38 a year ago.

Similar Private Companies By Industry

Company Name Region
Selectide Corporation United States
Hepregen Corporation United States
BME Systems, Inc. United States
Gilead Pharmasset LLC United States
Tetracore, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 30, 2014
--
Merger/Acquisition
April 16, 2014
Zalicus Inc.
Private Placement
April 16, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIRUS Biopharmaceuticals, Inc., please visit www.epirusbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.